Cecilia E. Verrillo

Cecilia E. Verrillo

Auto-generated profile, based on publicly available information

Cecilia E. Verrillo

Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Matrix Biology
Verified
Journal Article
Open access
ATAnna Testa
Anna Testa
FQFabio Quaglia
Fabio Quaglia
NNNicole M. Naranjo
Nicole M. Naranjo
CVCecilia E. Verrillo
Cecilia E. Verrillo
CSChristopher D. Shields
Christopher D. Shields
LLLucia R. Languino
Lucia R. Languino
Highly aggressive, metastatic, neuroendocrine prostate cancer, which typically develops from prostate cancer cells acquiring resistance to androgen deprivation therapy, is associated with limited treatment options and hence poor prognosis. We have previously demonstrated that the αVβ3 integrin is over-expressed in neuroendocrine prostate cancer. We now show that LM609, a monoclonal antibody that specifically targets the human αVβ3 integrin, hinders the growth of neuroendocrine prostate cancer patient-derived xenografts in vivo. Our group has recently identified a novel αVβ3 integrin binding partner, NgR2, responsible for regulating the expression of neuroendocrine markers and for inducing neuroendocrine differentiation in prostate cancer cells. Through in vitro functional assays, we here demonstrate that NgR2 is crucial in promoting cell adhesion to αVβ3 ligands. Moreover, we describe for the first time co-fractionation of αVβ3 integrin and NgR2 in small extracellular vesicles derived from metastatic prostate cancer patients' plasma. These prostate cancer patient-derived small extracellular vesicles have a functional impact on human monocytes, increasing their adhesion to fibronectin. These monocytes, upon incubation with small extracellular vesicles, do not show an associated change in conventional polarization marker expression and appear to be in an early stage that may be defined as "adhesion competent". Overall, these findings allow us to better understand integrin-directed signaling and cell-cell communication during cancer progression. Furthermore, our results pave the way for new diagnostic and therapeutic perspectives for patients affected by neuroendocrine prostate cancer.

27 April 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
CBCandice L. Bizzaro
Candice L. Bizzaro
CBCamila A. Bach
Camila A. Bach
RSRicardo A. Santos
Ricardo A. Santos
CVCecilia E. Verrillo
Cecilia E. Verrillo
NNNicole M. Naranjo
Nicole M. Naranjo
Lucia LanguinoLucia Languino
Lucia Languino
The six-transmembrane epithelial antigen of the prostate (STEAP; STEAP1 and STEAP2) metalloreductases are therapeutic targets for advanced prostate cancer, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and functions of STEAP1 and STEAP2 in prostate cancer progression remain elusive. In this study, we explore how in vitro androgen modulation and AR inhibition influence the expression of STEAP family members in cell lines with varying reliance on androgen signaling. Our data show that in response to androgen deprivation, STEAP1 and STEAP2 exhibit elevated transcript levels, whereas STEAP4 levels are reduced, mirroring the expression profile of kallikrein-related peptidase 3 (KLK3). As STEAP1 and STEAP2 are implicated in the exocytic pathway, we evaluated expression profiles in small extracellular vesicles (sEV) released from prostate cancer cells and in circulating sEVs. STEAP1, but not STEAP2, is upregulated in sEVs from AR-negative cells, which express low cellular STEAP1, and AR-positive cells, which express high cellular STEAP1. These results indicate selective packaging of STEAP1 in prostate cancer cell–derived sEVs, irrespective of AR status and cellular STEAP1 expression levels. Finally, ex vivo analysis of circulating sEVs from genetically engineered mice carrying prostate cancer shows that STEAP1 is found in the sEV cargo and that its levels are independent of protumorigenic β1 integrin expression in the prostatic epithelium. Implications: Understanding how androgen dependence affects STEAP1 expression in both tumor cells and sEVs across distinct disease stages will illuminate the clinical benefit of combinatorial AR and STEAP1-directed therapies and inform the optimal placement of STEAP1 targeting within the prostate cancer disease continuum.

3 June 2025
Verified
Other
Open access
CBCandice L. Bizzaro
Candice L. Bizzaro
CBCamila A. Bach
Camila A. Bach
RSRicardo A. Santos
Ricardo A. Santos
CVCecilia E. Verrillo
Cecilia E. Verrillo
NNNicole M. Naranjo
Nicole M. Naranjo
Lucia LanguinoLucia Languino
Lucia Languino
The six-transmembrane epithelial antigen of the prostate (STEAP; STEAP1 and STEAP2) metalloreductases are therapeutic targets for advanced prostate cancer, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and functions of STEAP1 and STEAP2 in prostate cancer progression remain elusive. In this study, we explore how in vitro androgen modulation and AR inhibition influence the expression of STEAP family members in cell lines with varying reliance on androgen signaling. Our data show that in response to androgen deprivation, STEAP1 and STEAP2 exhibit elevated transcript levels, whereas STEAP4 levels are reduced, mirroring the expression profile of kallikrein-related peptidase 3 (KLK3). As STEAP1 and STEAP2 are implicated in the exocytic pathway, we evaluated expression profiles in small extracellular vesicles (sEV) released from prostate cancer cells and in circulating sEVs. STEAP1, but not STEAP2, is upregulated in sEVs from AR-negative cells, which express low cellular STEAP1, and AR-positive cells, which express high cellular STEAP1. These results indicate selective packaging of STEAP1 in prostate cancer cell–derived sEVs, irrespective of AR status and cellular STEAP1 expression levels. Finally, ex vivo analysis of circulating sEVs from genetically engineered mice carrying prostate cancer shows that STEAP1 is found in the sEV cargo and that its levels are independent of protumorigenic β1 integrin expression in the prostatic epithelium.Implications:Understanding how androgen dependence affects STEAP1 expression in both tumor cells and sEVs across distinct disease stages will illuminate the clinical benefit of combinatorial AR and STEAP1-directed therapies and inform the optimal placement of STEAP1 targeting within the prostate cancer disease continuum.

3 June 2025
Verified
Other
Open access
PDF file
CBCandice L. Bizzaro
Candice L. Bizzaro
CBCamila A. Bach
Camila A. Bach
RSRicardo A. Santos
Ricardo A. Santos
CVCecilia E. Verrillo
Cecilia E. Verrillo
NNNicole M. Naranjo
Nicole M. Naranjo
Lucia LanguinoLucia Languino
Lucia Languino
Supplemental Table S5: Immunoblotting results of mouse PCa derived sEVs

3 June 2025
Verified
Other
Open access
PDF file
CBCandice L. Bizzaro
Candice L. Bizzaro
CBCamila A. Bach
Camila A. Bach
RSRicardo A. Santos
Ricardo A. Santos
CVCecilia E. Verrillo
Cecilia E. Verrillo
NNNicole M. Naranjo
Nicole M. Naranjo
Lucia LanguinoLucia Languino
Lucia Languino
Particle size distributions obtained by Nanoparticle tracking analysis (NTA) of sEVs derived from β1 FF or β1 FF TR mouse plasma (A-B) NTA measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) β1 FF or (B) β1 FF TR mouse plasma.

3 June 2025
Verified
Other
Open access
PDF file
CBCandice L. Bizzaro
Candice L. Bizzaro
CBCamila A. Bach
Camila A. Bach
RSRicardo A. Santos
Ricardo A. Santos
CVCecilia E. Verrillo
Cecilia E. Verrillo
NNNicole M. Naranjo
Nicole M. Naranjo
Lucia LanguinoLucia Languino
Lucia Languino
STEAP expression changes with DHT dose response Relative mRNA expression of (A) STEAP2 and STEAP4 in LNCaP cells and (B) STEAP1, STEAP2, STEAP4 and KLK3 expression in C42 cells treated with 0 nM (DMSO), 0.1 nM, 1 nM, and 10 nM DHT for 24 hours in regular growth or CSS conditions. P-values were calculated using two-way ANOVA followed by post-hoc Tukey test for multiple comparisons.